April 2020: Capital increase with public offering

Improved efficacy despite dose reduction due to multi-level glycan targeting – basic therapeutic cytostatic agents for the first time applied specifically in tumor tissu

Patented technology – based on many years of research

Reduced side effects – healthy tissue is optimally protected by the liposomal encapsulation of the drug

Existing agent subject to innovation – simpler registration with Swissmedic due to already approved active agent

Operating license from Swissmedic for proprietary clean room facility for GMP-production obtained

Chemotherapy is considerably more tolerable by the use of targeting systems reducing side-effects to a minimum

Drug delivery is poised to change the way doctors practice medicine – The Scientist, 2014

Together for the patient – planning of clinical trials in collaboration with Swiss Group for Clinical Cancer Research (SAKK)